-
Nepal floods leave trail of destruction, aid challenge
-
Kinshasa urban train back on track after years to beat gridlock
-
Experts outline sustainable ways to declutter Australian homes
-
Merino crossbreeding plan tests Himachal Pradesh wool ambitions
-
Bulk book purchases feed AI training through destructive scanning
-
Pringles launches thicker Dippers range for US snack market
-
George and Amal Clooney attend Lake Como event after France evacuation
-
US and Venezuela announce 65-billion-barrel oil development agreement
-
Michelle Obama describes relief and adjustment after daughters leave home
-
Assistance-dog dispute puts Great Bernera community groups under financial strain
-
Very strong El Niño forecast to peak during southern African summer
-
Sello Hatang remembers actor Sol Rachilo through a personal archive
-
SAFA opens tender for dressing rooms, ablutions and grandstands
-
UN committee calls on South Africa to dismantle racist vigilante groups
-
TEEKS brings Māori-rooted soul and a new view of masculinity to South Africa
-
South African creators seek stronger businesses beyond brand partnerships
-
Saudi customs seize 1.95 million amphetamine pills in lentil shipment
-
Syria warns Israeli actions could push region toward wider war
-
Trump says Russia will not attack NATO as CIA chief visits Moscow
-
East Midlands Railway warns of bank holiday disruption at St Pancras
-
British Museum schedules new Bayeux Tapestry ticket release
-
Six treated after sign falls at Big Church Festival in West Sussex
-
From forced labour to living heritage: Sao Tome's colonial plantations
-
Norway, in mourning, enters a new era under Haakon VIII
-
Motorola September 2026 Deals: Up to $700 Off Razr Ultra and Moto G
-
Number of missing in Nepal, China floods soars to nearly 3,000
-
In war-split Myanmar 'spirit consorts' commune across divide
-
Number of missing in Nepal, China floods soars past 2,400
-
Leaders of Russia, China, Iran to attend summit in Kyrgyzstan
-
Trump announces deal for huge US stake in Venezuelan oil reserves
-
Hovland and Gerard share lead at Tour Championship
-
Kane confirms talks on Bayern extension
-
Maresca salutes 'unbelievable' Cherki after Man City star sinks Palace
-
Trump govt. mulls deal to give away part of Yosemite park
-
Marquinhos rescues last-gasp draw for PSG at Lille in Ligue 1
-
Indian release of Sonia Gandhi memoir uncertain after publisher clarification
-
ICE detains British far-right activist Milo Yiannopoulos in Louisiana
-
Cities show cleaner transport policies can reduce severe air pollution
-
Milo Yiannopoulos held by ICE after missing immigration hearing
-
Four patients harmed in Nashville hospital medication mix-up
-
Six Flags closes X2 rollercoaster after reports of severe brain injuries
-
Essex council hires private guards as Wethersfield asylum centre expands
-
Jury ends second day without verdict in Lindsay Clancy murder trial
-
Haakon VIII becomes Norway's king after Harald V dies at 89
-
Artist says criticised Ronnie O'Sullivan mural is unfinished
-
Six injured after sign falls at Christian festival in West Sussex
-
UAE grants Starlink 10-year satellite broadband licence
-
Dubai airport expands scanners that keep laptops and liquids in bags
-
US says Hormuz mines cleared as diplomacy and military deployments continue
-
Kuwait and Pakistan sign military cooperation agreement
Study shows how fast kilos return after ending weight-loss drugs
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.
But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.
A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.
They have been found to help people lose between 15-20 percent of their body weight.
"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.
However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.
This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.
So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.
Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.
While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.
However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.
The researchers projected that the participants would return to their original weight in 18 months.
Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.
People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.
This meant that people taking the drugs regained their weight four times faster.
- 'Starting point, not a cure' -
"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.
But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.
This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.
Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."
"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.
If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.
"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.
"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.
H.Darwish--SF-PST